Graybug Vision to Participate in Upcoming Industry Conferences


Redwood City, CA – November 6, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for vision-threatening diseases including wet (neovascular) age-related macular degeneration (AMD) and glaucoma, today announced that Jeffrey L. Cleland, Ph.D., President and CEO, will present at the following upcoming investor and industry conferences:

  • Stifel 2017 Healthcare Conference
    Lotte New York Palace Hotel, New York City
    Wednesday, November 15 at 2:00 pm – 2:40 pm
  • 29th Annual Piper Jaffray Healthcare Conference
    Lotte New York Palace Hotel, New York City
    Tuesday, November 28 at 3:50 pm – 4:10 pm

Graybug Vision’s lead product, GB-102, is a novel injectable depot formulation containing a compound that blocks angiogenesis pathways through multiple receptors (e.g., VEGFR) with the potential to reduce the treatment of wet AMD to two intravitreal injections per year.  A Phase 1/2 study of GB-102 in wet AMD patients was recently initiated.  The first part of this study consists of an open label single ascending dose of GB-102 in wet AMD patients that have previously received anti-VEGF therapy.  Monthly assessments for safety, pharmacology (retinal fluid) and efficacy (visual acuity) are being conducted after the GB-102 injection. A second-generation GB-102 product, GB-103, for potential once per year treatment of wet AMD is also in preclinical development.  In addition, preclinical studies are ongoing to select one or more novel compounds for the twice per year treatment of glaucoma.

About Wet AMD
Wet (neovascular) age-related macular degeneration (wet AMD), is the leading cause of blindness in the developed world in individuals aged 50 years or older. It is caused by the formation of abnormal and leaky new blood vessels behind the retina, termed choroidal neovascularization. The leakage of fluid and protein from the vessels, causes retinal degeneration and leads to severe and rapid loss of vision. According to the National Eye Institute, the prevalence of wet AMD among adults 40 years or older in the U.S. alone is estimated at 1.75 million people. In addition, more than 200,000 new cases are diagnosed annually in the U.S.

About Graybug Vision
Graybug Vision is developing novel products for the treatment of people with ocular diseases.  The company’s proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases. The company’s lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD.  Graybug Vision has developed a library of compounds to treat glaucoma, a leading cause of progressive, irreversible vision loss worldwide, by lowering intraocular pressure alone or in combination with neuroprotection when injected twice per year.
For more information, please visit 
www.graybug.com.

Investors/Media
Jeff Cleland
jcleland@graybug.com
650-487-2808

 

 

Related News

Press release

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet Age-related Macular Degeneration

– Novel Injectable Formulation for Potential Twice Per Year Treatment – Redwood City, CA – September 19, 2017 – Graybug Vision, Inc., a clinical-stage, venture-held pharmaceutical company committed to developing potentially transformative therapies for vision-threatening Read more…

Press release

Graybug Vision CEO to Participate in OIS@ASRS Conference

– Company to Discuss Upcoming Phase 1/2 Study of Twice Per Year Treatment for AMD – Redwood City, CA – August 8, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially Read more…

Press release

Valerie Smith Joins Graybug Vision as VP, Global Clinical Development Operations

Redwood City, CA – May 8, 2017 – Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, today announced that Read more…